BofA Starts Coverage of Inhibikase Therapeutics with Buy Rating
BofA gives Inhibikase Therapeutics (IKT) a Buy rating with $6 target, citing strong data, regulatory support, and promising leukemia therapy for PAH.
NOTRELOAD AI
Bank of America Turns Bullish on Oklo After Major Meta Deal
Bank of America upgraded Oklo stock to Buy after a binding deal with Meta to build a 1.2 GW nuclear campus, highlighting growing data center demand.
RBC Capital Turns Bullish on Biohaven: Big Upgrade and Higher Price Target
RBC Capital upgrades Biohaven to Outperform, raises price target to $22, and highlights improving data, lower risk, and strong 2026 catalysts.
Berkshire Hathaway May Exit Kraft Heinz Investment After Years of Struggles
Kraft Heinz shares fell 5% after Berkshire Hathaway filed to potentially sell its entire 27% stake worth $7.7 billion, marking the end of a disappointing decade-long investment.
BofA Upgrades Apellis as Empaveli Shows Strong Early Momentum
Bank of America upgraded Apellis to Buy, citing undervalued shares and strong early uptake of Empaveli in rare kidney diseases.
Serve Robotics Expands into Healthcare with Diligent Robotics Acquisition
Serve Robotics acquires Diligent Robotics for $29M, moving beyond sidewalk delivery into hospital automation with Moxi robots serving healthcare facilities nationwide.